Development of new dehydrocostuslactone derivatives for treatment of atopic dermatitis inhibition of the NF-κB signaling pathway.

Atopic dermatitis (AD), a recurrent inflammatory systemic skin disease, is difficult to cure. In the present study, several ethylenediamine-derived dehydrocostuslactone (DHCL) derivatives were prepared to assess their and anti-inflammatory activities. The results indicated that DHCL derivatives inhibited NO generation with low cytotoxicity.